Homayoon Yektaei, Hanieh Yektaei, Yasaman Hoseyni
Heart health has always been a major concern for both humans and animals alike. With cardiovascular diseases on the rise, medical professionals are constantly striving to find innovative solutions that can reduce the burden of heart surgeries and improve overall cardiac health. Nanomedicine is one of the most promising therapeutic modalities researchers are working on. It involves development of drugs and devices that work at the nanoscale. We are leading a research wich has a groundbreaking drug emerged, which holds enormous potential in preventing the need for heavy heart operations. This wonder drug, with its unique mechanism of action, breaks down LDL and HDL fats in the heart veins and efficiently directs them towards elimination, safeguarding the heart from potential harm. The drug, which specifically targets the heart, has been engineered to selectively break down LDL (low-density lipoprotein) and HDL (high-density lipoprotein) fats present in the heart veins. These fats, if left untreated, can accumulate and form plaques, leading to a condition called atherosclerosis. This condition obstructs blood flow to the heart, increasing the risk of heart attacks or strokes. By effectively breaking down these harmful fats, the drug prevents the development of atherosclerosis and subsequently mitigates the need for complex heart surgeries.
